MSD and Eisai’s Keytruda/Lenvima Combo Shows Promise in Gastroesophageal Cancer Study
Partners Merck, Sharp & Dohme (MSD, NYSE: MRK) and Eisai (TYO: 4523) have announced the...
NHSA Targets Low-Volume Drugs in National Reimbursement List
The National Healthcare Security Administration (NHSA) in China has released a list of 131 drugs...
Novo Nordisk’s Amycretin Shows Promising Weight Loss Results in Phase Ib/IIa Study
Denmark – based pharmaceutical giant Novo Nordisk A / S (NYSE: NVO) has announced topline...
Jiangsu Vcare PharmaTech Secures RMB200 Million in Series C+ Financing
Jiangsu Vcare PharmaTech Co., Ltd., a China – based high – tech pharmaceutical company, has...
GeneQuantum Secures $13 Billion Deals with Biohaven and AimedBio for ADC Development
Suzhou based biotech firm GeneQuantum has announced a series of major commercial cooperation pacts worth...
Sinopharm Partners with Biogen for Comprehensive Service Agreement
China-based Sinopharm Group Co., Ltd (HKG: 1099) has entered into a strategic partnership with US-based...
Boehringer Ingelheim’s Nerandomilast Granted Priority Review for IPF in China
German pharmaceutical giant Boehringer Ingelheim has announced that the Center for Drug Evaluation (CDE) of...
Mirxes Holding Files for Hong Kong IPO with Focus on miRNA Test Kits
Mirxes Holding Company Ltd, a Singapore – headquartered RNA technology company, has received a filing...
Shenzhen Kangtai Halts COVID-19 Vaccine Development Amid Market Shifts
Shenzhen based biopharmaceutical company Shenzhen Kangtai Biological Products Co., Ltd (SHE: 300601) has announced the...
Huadong Medicine’s Ellansé M Filing Accepted by China’s NMPA
China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced that its market filing for the...
China Medical System Partners with MabGeek for Innovative Drug MG-K10
China Medical System Holdings (CMS; HKG: 0867) has announced a new license agreement with MabGeek...
BioCity Biopharma Launches Phase III Study for Kidney Disease Drug SC0062
BioCity Biopharma, a leading biopharmaceutical company, has announced the initiation of a Phase III clinical...
ConjuStar Raises RMB100 Million to Advance X-Drug Conjugates Pipeline
ConjuStar, a specialist in X-Drug conjugates (XDCs) based in Tianjin, has reportedly raised RMB100 million...
Hengrui’s Long-Acting Insulin Analogue Accepted for Review by China’s NMPA
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has announced that its market filing for...
AbbVie Partners with Neomorph on Molecular Glue Degraders for Oncology and Immunology
US-based pharmaceutical giant AbbVie (NYSE: ABBV) has entered into a collaboration and option-to-license agreement with...
Sino Medical Sciences Wins Peru Approval for Coronary Balloon Catheter
China-based Sino Medical Sciences Technology Inc. (SHA: 688108) has announced receiving marketing approval from Peru’s...
Shenzhen Beike Initiates First Chinese Stem Cell Study for Systemic Lupus Erythematosus
China-based stem cell specialist Shenzhen Beike Biotechnology Co., Ltd has announced the initiation of a...
Accuray’s Tomo C System Completes Treatment of First 100 Patients in China
US-based medical device firm Accuray Inc. (NASDAQ: ARAY) has announced the completion of treating the...
Ascentage Pharma Prices US IPO at USD 17.25 per ADS
China-based Ascentage Pharma (NASDAQ: AAPG, HKG: 6855) has announced the pricing of its initial public...
United Laboratories’ Biosimilar Semaglutide Accepted for Review by China’s NMPA
Hong Kong-listed United Laboratories International Holdings Ltd (HKG: 3933) has announced that its market filing...